---
figid: PMC5730634__10557_2017_6757_Fig1_HTML
figtitle: Effects of vascular disease treatment on pMV release
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5730634
filename: 10557_2017_6757_Fig1_HTML.jpg
figlink: /pmc/articles/PMC5730634/figure/Fig1/
number: F1
caption: Potential effects of vascular disease treatment on pMV release. Increase
  in intraplatelet calcium concentration is the principal step in pMV formation. ADP
  receptor inhibitors increase the intraplatelet concentration of cAMP thereby decreasing
  platelet vesiculation. GP IIb-IIIa antagonists inhibit binding of fibrinogen thereby
  preventing the second wave of platelet activation. Statins inhibit platelet vesiculation
  multi-directional—reducing NF-κB activity and increasing exposure of PPARs and via
  the ROCK pathway. Fibrates as PPAR agonists increase the levels of both cAMP and
  cGMP and decrease calcium concentration. Calcium channel blockers inhibit calcium
  influx and decrease intracellular calcium concentration. Platelet-derived microvesicles
  transfer AA between platelets and ECs. Microvesicles also metabolize AA to TXA2.
  AA arachidonic acid, ADP adenosine diphosphate, ASA acetylsalicylic acid, COX cyclooxygenase,
  GP glycoprotein, MLCP myosin light chain phosphatise, MAPK mitogen-activated protein
  kinase, NF-κB nuclear factor kappa B, PDE phosphodiestherase, PGH2 prostaglandin
  H2, PKC protein kinase C, PLA2 phospholipase A2, PLT platelet, p38MAPK mitogen-activated
  protein kinase p38, pMV platelet-derived microvesicles, PPAR peroxisome proliferator-activated
  receptor, PS phosphatidylserine, PUFAs polyunsaturated fatty acids, ROCK Rho-associated
  protein kinase, TNF-α tumor necrosis factor α, TXA2 thromboxane A2, TXA2R thromboxane
  A2 receptor
papertitle: The Impact of Vascular Disease Treatment on Platelet-Derived Microvesicles.
reftext: Justyna Rosińska, et al. Cardiovasc Drugs Ther. 2017;31(5):627-644.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9104021
figid_alias: PMC5730634__F1
figtype: Figure
redirect_from: /figures/PMC5730634__F1
ndex: 950210b7-df11-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5730634__10557_2017_6757_Fig1_HTML.html
  '@type': Dataset
  description: Potential effects of vascular disease treatment on pMV release. Increase
    in intraplatelet calcium concentration is the principal step in pMV formation.
    ADP receptor inhibitors increase the intraplatelet concentration of cAMP thereby
    decreasing platelet vesiculation. GP IIb-IIIa antagonists inhibit binding of fibrinogen
    thereby preventing the second wave of platelet activation. Statins inhibit platelet
    vesiculation multi-directional—reducing NF-κB activity and increasing exposure
    of PPARs and via the ROCK pathway. Fibrates as PPAR agonists increase the levels
    of both cAMP and cGMP and decrease calcium concentration. Calcium channel blockers
    inhibit calcium influx and decrease intracellular calcium concentration. Platelet-derived
    microvesicles transfer AA between platelets and ECs. Microvesicles also metabolize
    AA to TXA2. AA arachidonic acid, ADP adenosine diphosphate, ASA acetylsalicylic
    acid, COX cyclooxygenase, GP glycoprotein, MLCP myosin light chain phosphatise,
    MAPK mitogen-activated protein kinase, NF-κB nuclear factor kappa B, PDE phosphodiestherase,
    PGH2 prostaglandin H2, PKC protein kinase C, PLA2 phospholipase A2, PLT platelet,
    p38MAPK mitogen-activated protein kinase p38, pMV platelet-derived microvesicles,
    PPAR peroxisome proliferator-activated receptor, PS phosphatidylserine, PUFAs
    polyunsaturated fatty acids, ROCK Rho-associated protein kinase, TNF-α tumor necrosis
    factor α, TXA2 thromboxane A2, TXA2R thromboxane A2 receptor
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - sbb
  - E(Mer)IIb
  - gp
  - ps
  - ca
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - AstA
  - beta-Spec
  - alpha-Spec
  - adp
  - Decay
  - Rok
  - aa
  - p38b
  - p38a
  - p38c
  - egr
  - an
  - Dif
  - dl
  - Rel
  - Low
  - COX2
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - COX4
  - COX5A
  - NAAA
  - MMVP1
  - ITGA2B
  - FGA
  - FGB
  - FGG
  - ARSA
  - P2RY12
  - WDTC1
  - ROCK1
  - ROCK2
  - TNF
  - AN
  - TBXA2R
  - NFKB1
  - PTGS2
  - PDE3A
  - PDE3B
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - COX8A
  - CPOX
  - COX5B
  - COX6C
  - COX7C
  - .na.character
  - COX4I1
  - COX4I2
  - COX6A1
  - COX6A2
  - COX6B1
  - COX6B2
  - COX7A1
  - COX7A2
  - COX7B
  - COX7B2
  - COX8C
---
